A phase II study of imatinib in patients with advanced anaplastic thyroid cancer

Thyroid

Volumn 20, Issue 9, 2010, Pages 975-980

  Ha, Huan T ^a   Lee, Julia S ^b   Urba, Susan ^a   Koenig, Ronald J ^a   Sisson, James ^a   Giordano, Thomas ^a   Worden, Francis P ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALLERGIC RHINITIS; ALOPECIA; AMNESIA; ANAPLASTIC THYROID CANCER; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ATAXIA; BLURRED VISION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COUGHING; DEHYDRATION; DIARRHEA; DISEASE COURSE; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEMALE; FOLLOW UP; GENE EXPRESSION; HEMOPTYSIS; HISTOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPONATREMIA; HYPOTHYROIDISM; HYPOXIA; IMMUNOHISTOCHEMISTRY; INFECTION; LIVER FUNCTION TEST; LYMPHOCYTOPENIA; MALE; MELENA; MENTAL HEALTH; MOOD; MYALGIA; NAUSEA; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SYNCOPE; THORAX PAIN; THROMBOCYTOPENIA; THYROID CANCER; THYROIDECTOMY; TREATMENT RESPONSE; URINARY URGENCY; VOMITING; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; THYROID NEOPLASMS;

EID: 77956519744     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2010.0057     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ 2008 Cancer statistics, 2008. CA Cancer J Clin 58:71-96.
2. Ain KB 1998 Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8:715-726.
3. Ain KB 1999 Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 16:64-69.
4. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, Goellner JR 2001 Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130:1028-1034.
5. Are C, Shaha AR 2006 Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13:453-464.
6. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA 1990 Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 66:321-330.
7. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A 2001 Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 25:617-622.
8. Besic N, Hocevar M, Zgajnar J, Pogacnik A, Grazio-Frkovic S, Auersperg M 2005 Prognostic factors in anaplastic carcinoma of the thyroid-a multivariate survival analysis of 188 patients. Langenbecks Arch Surg 390:203-208.
9. Ahuja S, Ernst H 1987 Chemotherapy of thyroid carcinoma. J Endocrinol Invest 10:303-310.
10. Ain KB, Egorin MJ, DeSimone PA 2000 Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587-594.
11. Whang YE, Tran C, Henderson C, Syljuasen RG, Rozengurt N, McBride WH, Sawyers CL 2000 c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency. Proc Natl Acad Sci USA 97:5486-5491.
12. Zou M, Shi Y, Farid NR 1993 p53 mutations in all stages of thyroid carcinomas. J Clin Endocrinol Metab 77:1054-1058.
13. Lam KY, Lo CY, Chan KW, Wan KY 2000 Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg 231:329-338.
14. Wiseman SM, Loree TR, Rigual NR, Hicks WL Jr., Douglas WG, Anderson GR, Stoler DL 2003 Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck 25:662-670.
15. Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, Nakashima M, Mitsutake N, Kanda S, Kurebayashi J, Yamashita S 2003 The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88:1889-1896.
16. Kurebayashi J, Okubo S, Yamamoto Y, Ikeda M, Tanaka K, Otsuki T, Sonoo H 2006 Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother Pharmacol 58:460-470.
17. Rao AS, Kremenevskaja N, von Wasielewski R, Jakubcakova V, Kant S, Resch J, Brabant G 2006 Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer. J Clin Endocrinol Metab 91:159-168.
18. Heldin NE, Gustavsson B, Claesson-Welsh L, Hammacher A, Mark J, Heldin CH, Westermark B 1988 Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line. Proc Natl Acad Sci USA 85:9302-9306.
19. Heldin NE, Cvejic D, Smeds S, Westermark B 1991 Coexpression of functionally active receptors for thyrotropin and platelet-derived growth factor in human thyroid carcinoma cells. Endocrinology 129:2187-2193.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216.
21. National Cancer Institute 1993 Investigators Handbook: A Manual for Participants in Clinical Trials of Investigational Agents Sponsored by DCTD, NCI. National Cancer Institute, Bethesda, MD.
22. Simon R 1989 Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10.
23. Carey VJ 1997 Using hypertext and the Internet for structure and management of observational studies. Stat Med 16: 1667-1682.
24. Dziba JM, Ain KB 2004 Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro. J Clin Endocrinol Metab 89:2127-2135.
25. Lange T, Gunther C, Kohler T, Krahl R, Musiol S, Leiblein S, Al-Ali HK, van Hoomissen I, Niederwieser D, Deininger MW 2003 High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood 101:2152-2155.
26. Theou N, Gil S, Devocelle A, Julie C, Lavergne-Slove A, Beauchet A, Callard P, Farinotti R, Le Cesne A, Lemoine A, Faivre-Bonhomme L, Emile JF 2005 Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Clin Cancer Res 11:7593-7598.
27. Nagaiah G, Fu P, Wasman JK, Cooney MM 2009 Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC). J Clin Oncol 27(15 suppl).
28. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle- Teijeiro J, Santoro M 2005 Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65:10199-10207.
29. Paes JE, Ringel MD 2008 Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am 37:375-387, viii-ix.
30. Kim JH, Leeper RD 1987 Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 60:2372-2375.
31. Podtcheko A, Ohtsuru A, Namba H, Saenko V, Starenki D, Palona I, Sedliarou I, Rogounovitch T, Yamashita S 2006 Inhibition of ABL tyrosine kinase potentiates radiationinduced terminal growth arrest in anaplastic thyroid cancer cells. Radiat Res 165:35-42.